M A L O N E . N E W S
Forty-Four Billion Dollars, No Data
Moderna and Merck say their personalized mRNA cancer therapy worked in a large melanoma trial. They have not yet shown anyone the data. The distance between those two facts is the story.
By Robert W. Malone, MD, MS, and Jill Glasspool Malone, PhD
On the morning of August 19, Merck and Moderna issued a press release. It said that a large clinical trial of a personalized mRNA product, given alongside Merck’s cancer drug Keytruda, had succeeded in patients whose melanoma had been surgically removed (Merck and Moderna 2026a).
By the closing bell, Moderna’s stock had risen 177 percent. The company’s market value went from about $25 billion to about $69 billion in one trading session. Trading volume ran roughly nineteen times its three-month average (Motley Fool 2026). Merck gained more than 12 percent (CNBC 2026). Headlines around the world announced that an mRNA cancer vaccine had finally worked.
We should be plain about our interest before going further. One of us designed and implemented the core messenger RNA construct that remains in use today. He also developed the benchtop version of the manufacturing process the industry later scaled, and wrote the initial patent disclosures in the late 1980s covering the use of RNA as a drug and its application to vaccination. That is the documented basis for the claim to original inventorship of this platform. It rests on the patent record and its filing dates.
It has never included a claim to have invented the COVID vaccines, or to have worked alone. Read what follows as the assessment of people who would like this technology to succeed, and who also read the fine print.
The press release contains no numbers.
What the product is
Some vocabulary first, because the coverage has been sloppy with it.
Every tumor carries mutations. Those mutations produce slightly altered proteins that the patient’s own healthy cells do not make. Immunologists call these altered proteins neoantigens, meaning new antigens. In principle, they are flags the immune system could learn to recognize.
The Merck and Moderna product, now named intismeran autogene, works from that idea. A surgeon removes the tumor. A laboratory sequences it and identifies mutations unique to that patient. Software picks up to 34 of them. A custom mRNA molecule is then synthesized that instructs the patient’s cells to manufacture those specific flagged proteins, wrapped in the same fatty particles used in the COVID shots (Merck and Moderna 2026a).
The patient receives nine injections over about six months. That is the Moderna component alone. Counted alongside the Keytruda infusions, the earlier trial asked patients for twenty-seven administrations across a year, and the current one asks for eighteen (Weber et al. 2024; Merck and Moderna 2026a). Claims circulating online that Moderna's product is itself an eighteen- or twenty-seven-injection course are wrong. Those totals include Merck's antibody drug, which has been in use since 2014 and is given intravenously.
Keytruda does something different. It releases a brake that tumors use to switch off immune cells that would otherwise attack them. The theory of the combination is that one drug supplies the target and the other removes the restraint.
Moderna no longer calls this a vaccine. The company calls it an individualized neoantigen therapy, and that is the honest description (Boston Globe 2026). Nobody is preventing melanoma with this. It is given to people who already had the disease cut out, to reduce the chance that it returns. Physicians call that adjuvant treatment. Most of the press has gone on using the word vaccine anyway, and that word is doing work in this debate that the underlying science does not support.
What the announcement actually said
The trial is called INTerpath-001. It enrolled 1,137 patients whose melanoma had been completely removed. Two-thirds received the personalized injections plus Keytruda. One third received Keytruda alone. Treatment ran about a year (Merck and Moderna 2026a).
The companies report that the combination beat Keytruda alone on two measures. The first is recurrence-free survival, meaning how long patients go before the cancer comes back or they die. The second is distant metastasis-free survival, meaning how long before the cancer appears somewhere far from the original site.
Now consider what the release does not contain. There is no hazard ratio, which is the standard measure of how much a treatment reduces risk. There is no confidence interval, which tells a reader how precise that estimate is. There is no p-value. There is no count of how many patients in each group actually relapsed. There are no survival curves. There is no breakdown by disease stage. The phrase used is “statistically significant and clinically meaningful,” which is a claim about numbers rather than the numbers themselves.
The release is not short on language, only on data. Professor Georgina Long of Melanoma Institute Australia, the trial’s principal investigator, called the result “a landmark moment for adjuvant melanoma treatment” (AJMC 2026). Stephane Bancel, Moderna’s chief executive, described the findings as “a pivotal moment for the field of cancer research” (Merck and Moderna 2026a).
Both statements may prove correct. Neither can be checked by anyone outside the sponsor, because the release supplies no figure against which to test them.
A pharmaceutical company telling you its result was clinically meaningful, without showing you the result, is an advertisement. It may happen to be true. It may also fail to survive independent expert scrutiny.
Two further details in the release deserve attention. The result comes from a planned interim look, taken before the trial finished. Trials reported at the first moment they cross a statistical threshold tend to overstate the size of the benefit compared with the final tally. That is a known property of the method, not an accusation.
Interim looks are legitimate, and they exist for a sound reason. If a treatment is plainly working, it becomes hard to justify keeping the comparison group from it. But they are not free. Each look spends part of a fixed error budget, so whatever remains for the final analysis must clear a stricter bar, and trials are enlarged in advance to absorb the cost. The companies have not said how many looks were planned, how much of the budget this one consumed, or which threshold it crossed. Without those three figures, a reader outside the sponsor cannot judge how strong the result was. Only that it was strong enough to announce.
Note also what did not happen. The trial did not stop. It continues to measure whether anyone lives longer. What ended early was the wait for a headline.
Overall survival, the measure of whether patients live longer, is not yet available. The release states plainly that the study continues in order to assess it (Merck and Moderna 2026a).
If you own MRNA or MRK, or watched Monday's move and wondered whether to chase it, the section you just read is the entire public factual basis for a 177 percent single-day gain. Everything below is what it didn't include.
The 157-patient trial this whole program rests on, and the confidence interval in its first published result that touched the line of no effect. The 53 percent survival improvement now circulating in the financial press, and why the study’s own authors labeled that number exploratory and not statistically valid. The comparison drug has been in trials since 2015 without anyone yet demonstrating that a single patient lived longer, which is the regulatory foundation this approval will be built on. Bank of America’s own admission that its team spoke with management before writing the note that moved the models, while retail investors got a press release with no effect size. JPMorgan’s arithmetic showing the melanoma result was worth roughly 3 percent of Moderna’s valuation, against a stock that doubled and then gave back 20 percent the next morning.
And the eight specific numbers to look for when the data are finally presented, which is when the market will find out whether Monday was information or enthusiasm.
We do not give investment advice, and we do not take pharmaceutical money or advertising. What we do is read the primary literature and report what it says, which is the same job the sell side does for its clients and does not do for you. Paid subscribers are why the work exists.
Free subscribers receive our public essays. Paid subscribers receive everything.
